<DOC>
	<DOC>NCT02995772</DOC>
	<brief_summary>This study compared long term outcome of stage IIIB/C and IV breast cancer patients treated with neoadjuvant hormonal therapy (NAHT) and those treated with neoadjuvant chemotherapy (NACT)</brief_summary>
	<brief_title>Neoadjuvant Hormonal Therapy Compared to Neoadjuvant Chemotherapy in Stage IIIB/C and IV Breast Cancer Patients</brief_title>
	<detailed_description>This study compared long term outcome of stage IIIB/C and IV breast cancer patients treated with neoadjuvant hormonal therapy (NAHT) and those treated with neoadjuvant chemotherapy (NACT) between 2011 and 2016. The primary end points are overall survival (OS) and progression free survival (PFS) with Kaplan Meier. This study was approved by Ethical Committee in Dharmais National Cancer Hospital.</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Aromatase Inhibitors</mesh_term>
	<mesh_term>Anastrozole</mesh_term>
	<mesh_term>Letrozole</mesh_term>
	<mesh_term>Exemestane</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<criteria>IIIB/C and IV stage of breast cancer received neoadjuvant hormonal therapy or neoadjuvant chemotherapy had first and second biopsy (surgery) within 6 months had mastectomy before treatment pregnant disagree to enter the study had been given hormonal therapy or chemotherapy before study had contraindication of SOB for premenopausal patients</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>